Latest Asx News

Orbminco Limited has successfully closed its entitlement offer, raising $0.23 million, while planning to place a significant shortfall of 852 million shares within the next three months.

BOA Resources is progressing its 2025 drilling plans across key lithium and nickel tenements in Western Australia, while managing delays in heritage surveys and optimizing its tenement portfolio to focus on high-potential assets.

Zelira Therapeutics has enhanced its financial flexibility through a $1.15 million R&D tax refund and a $1 million At-the-Market equity facility, while progressing FDA trial preparations for its HOPE® 1 autism treatment.

Rey Resources reported a net cash outflow in Q1 2025 while progressing seismic surveys and land access negotiations in Western Australia's Canning Basin. The company maintains significant loan facilities to support ongoing exploration activities.

Holista Colltech has closed its ASIC penalty chapter with a $900K final payment, raised $1.53 million through convertible notes, and reported a 10.9% year-on-year sales increase driven by its Dietary Supplements division.

Southern Cross Gold Consolidated has announced a substantial C$120 million private placement to fund key development phases at its Sunday Creek Gold-Antimony Project, aiming to fast-track drilling, decline construction, and resource expansion.

Electro Optic Systems (EOS) reported a robust quarter ending March 2025, highlighted by significant new defence contracts and a strong cash position following the divestment of its EM Solutions subsidiary.

4DMedical Limited reports a 103% surge in year-to-date revenue, secures major contracts with leading healthcare providers, and advances its CT:VQ™ technology towards FDA clearance.

Power Minerals Limited has raised $1.3 million through a placement to fund critical exploration and due diligence at its Santa Anna Niobium Carbonatite Project in Brazil, backed by a strategic investment from Golden Worldwide Holdings.

Identitii Limited advances its BNDRY platform with new agreements targeting hospitality and payments sectors, appoints Tim Phillipps as Executive Chair, and reports stable cash flow amid ongoing patent litigation.

Radiopharm Theranostics has bolstered its cash position with an $8 million placement from Lantheus Holdings, now its largest shareholder. New clinical data highlight promising advances in brain metastases detection and HER2-targeted radiopharmaceutical therapies.

ReNerve Limited reported a 39% sales increase in Q3 FY25 alongside compelling clinical validation of its NervAlign® Nerve Cuff and strategic international partnerships, positioning the company for broader market penetration.